Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Oncolytics Biotech Inc (ONCY)

Oncolytics Biotech Inc (ONCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 74,583
  • Shares Outstanding, K 75,420
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,560 K
  • 60-Month Beta 1.94
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.72
Trade ONCY with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.09
  • Number of Estimates 1
  • High Estimate -0.09
  • Low Estimate -0.09
  • Prior Year -0.07
  • Growth Rate Est. (year over year) -28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8855 +17.45%
on 03/04/24
1.1800 -11.86%
on 03/01/24
-0.1200 (-10.34%)
since 02/16/24
3-Month
0.8830 +17.78%
on 02/07/24
1.3950 -25.45%
on 01/02/24
-0.2300 (-18.11%)
since 12/18/23
52-Week
0.8830 +17.78%
on 02/07/24
3.3942 -69.36%
on 06/23/23
-0.3100 (-22.96%)
since 03/17/23

Most Recent Stories

More News
Biotech Sector Advances in Pancreatic Cancer Research

USA News Group – Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers today. However, researchers and the biotech sector are working...

BRX : 22.47 (+1.44%)
ONCY : 1.0400 (+5.17%)
ONC.TO : 1.42 (+5.97%)
NVS : 95.92 (-1.39%)
IBRX : 5.23 (+1.95%)
ACRS : 1.1500 (-1.71%)
NUVB : 2.26 (-0.88%)
Biotech’s Role in Addressing the Pancreatic Cancer Emergency

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVX),(NASDAQ:IBRX),(NASDAQ:ACRS),(NYSE:NUVB) EQNX::TICKER_END

NVX : 2.45 (-8.24%)
ONCY : 1.0400 (+5.17%)
ONC.TO : 1.42 (+5.97%)
NVS : 95.92 (-1.39%)
IBRX : 5.23 (+1.95%)
ACRS : 1.1500 (-1.71%)
NUVB : 2.26 (-0.88%)
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth

EQNX::TICKER_START (ONASDAQ:ONCY),(TSX:ONC),(NASDAQ:BLRX),(NASDAQ:IMRX),(NASDAQ:CADL) EQNX::TICKER_END

ONCY : 1.0400 (+5.17%)
ONC.TO : 1.42 (+5.97%)
BLRX : 1.1499 (-0.01%)
IMRX : 2.5600 (+34.03%)
CADL : 1.4000 (-6.67%)
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

Vancouver, Kelowna and Delta, British Columbia--(Newsfile Corp. - March 6, 2024) - Investorideas.com, a global investor news source covering biotech and pharma stocks issues a sector snapshot on developments...

ONCY : 1.0400 (+5.17%)
ONC.TO : 1.42 (+5.97%)
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:OCEA),(NASDAQ:LVTX),(NYSE:MRK),(NYSE:ABBV) EQNX::TICKER_END

OCEA : 4.05 (-1.70%)
ONCY : 1.0400 (+5.17%)
ONC.TO : 1.42 (+5.97%)
LVTX : 2.94 (-0.34%)
MRK : 121.44 (-0.07%)
ABBV : 178.49 (+0.34%)
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments

ONCY : 1.0400 (+5.17%)
ONC.TO : 1.42 (+5.97%)
LVTX : 2.94 (-0.34%)
MRK : 121.44 (-0.07%)
ABBV : 178.49 (+0.34%)
Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN

 US$5M grant supports study of pelareorep in combination with modified FOLFIRINOX +/- atezolizumab   Testing with the most common therapies could facilitate broad use of pelareorep in pancreatic cancer...

ONCY : 1.0400 (+5.17%)
ONC.TO : 1.42 (+5.97%)
Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced it has submitted...

ONCY : 1.0400 (+5.17%)
ONC.TO : 1.42 (+5.97%)
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced that it will host...

ONCY : 1.0400 (+5.17%)
ONC.TO : 1.42 (+5.97%)
Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced that Chief...

ONCY : 1.0400 (+5.17%)
ONC.TO : 1.42 (+5.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated...

See More

Key Turning Points

3rd Resistance Point 1.1500
2nd Resistance Point 1.1000
1st Resistance Point 1.0700
Last Price 1.0400
1st Support Level 0.9900
2nd Support Level 0.9400
3rd Support Level 0.9100

See More

52-Week High 3.3942
Fibonacci 61.8% 2.4349
Fibonacci 50% 2.1386
Fibonacci 38.2% 1.8423
Last Price 1.0400
52-Week Low 0.8830

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar